What British Minister Of Health Has To Say About The End Of AstraZeneca Vaccine Clinical Trial

The British Minister of Health affirmed that the decision to suspend the AstraZenec vaccine trial is a step to ensure the correct process, whenever an incident occurs, it is necessary to investigate and clarify.

UK Health Minister Matt Hancock has quickly defended AstraZeneca's decision to suspend phase 3 clinical trials on the vaccine sample developed by the company in cooperation with the University of Oxford for safety reasons.

Specifically, speaking on Sky News on 9/9, Mr. Hancock said that the fact that a volunteer participating in clinical trials suspected of having side effects is a challenge for the AstraZeneca vaccine sample.

However, Mr. Matt Hancock confirmed, this is not the first incident with this vaccine. The decision to suspend the test is a step to ensure the correct process, whenever there is a problem, it is necessary to investigate and clarify.

When asked about the impact of the event on potential vaccine development, Hancock said:

“It is not necessary to see this as a setback. It all depends on what the experts find out in the investigation.”

Earlier, on September 8, AstraZeneca announced that it would suspend the COVID-19 vaccine trial study called AZD1222, after a volunteer participating in a clinical trial showed signs of an unexplained illness.